Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: A Swedish national population-based register study | ||
| dc.conicet.organizacion | Karolinska Huddinge Hospital. Karolinska Institutet | |
| dc.conicet.organizacion | Karolinska Huddinge Hospital. Karolinska Institutet | |
| dc.conicet.organizacion | Consultant for Bayer AG | |
| dc.conicet.organizacion | Bayer AG | |
| dc.conicet.organizacion | Bayer AG | |
| dc.conicet.organizacion | Università di Perugia | |
| dc.conicet.organizacion | University of Ottawa | |
| dc.conicet.organizacion | Kings College London (kcl) | |
| dc.conicet.organizacion | University of Connecticut | |
| dc.conicet.organizacion | Cleveland Clinic and Case Comprehensive Cancer Center | |
| dc.conicet.organizacion | BC Cancer | |
| dc.conicet.organizacion | University of British Columbia | |
| dc.conicet.organizacion | Bayer AG | |
| dc.conicet.organizacion | Bayer AG | |
| dc.conicet.organizacion | Consultant for Bayer AG | |
| dc.conicet.organizacion | Bayer AG | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Karolinska Huddinge Hospital. Karolinska Institutet | |
| dc.contributor.author | Linder, Marie | |
| dc.contributor.author | Ekbom, Anders | |
| dc.contributor.author | Brobert, Gunnar | |
| dc.contributor.author | Vogtländer, Kai | |
| dc.contributor.author | Balabanova, Yanina | |
| dc.contributor.author | Becattini, Cecilia | |
| dc.contributor.author | Carrier, Marc | |
| dc.contributor.author | Cohen, Alexander T. | |
| dc.contributor.author | Coleman, Craig I. | |
| dc.contributor.author | Khorana, Alok A. | |
| dc.contributor.author | Lee, Agnes Y. Y. | |
| dc.contributor.author | Psaroudakis, George | |
| dc.contributor.author | Abdelgawwad, Khaled | |
| dc.contributor.author | Rivera, Marcela | |
| dc.contributor.author | Schaefer, Bernhard | |
| dc.contributor.author | Giunta, Diego Hernan | |
| dc.date.issued | 2024-05 | |
| dc.description.abstract | Background Treating cancer-associated venous thromboembolism (CAT) with anticoagulation prevents recurrent venous thromboembolism (rVTE), but increases bleeding risk. Objectives To compare incidence of rVTE, major bleeding, and all-cause mortality for rivaroxaban versus low molecular weight heparin (LMWH) in patients with CAT. Methods We developed a cohort study using Swedish national registers 2013–2019. Patients with CAT (venous thromboembolism within 6 months of cancer diagnosis) were included. Those with other indications or with high bleeding risk cancers were excluded (according to guidelines). Follow-up was from index-CAT until outcome, death, emigration, or end of study. Incidence rates (IR) per 1000 person-years with 95% confidence interval (CI) and propensity score overlap-weighted hazard ratios (HRs) for rivaroxaban versus LMWH were estimated. Results We included 283 patients on rivaroxaban and 5181 on LMWH. The IR for rVTE was 68.7 (95% CI 40.0–109.9) for rivaroxaban, compared with 91.6 (95% CI 81.9–102.0) for LMWH, with adjusted HR 0.77 (95% CI 0.43–1.35). The IR for major bleeding was 23.5 (95% CI 8.6–51.1) for rivaroxaban versus 49.2 (95% CI 42.3–56.9) for LMWH, with adjusted HR 0.62 (95% CI 0.26–1.49). The IR for all-cause mortality was 146.8 (95% CI 103.9–201.5) for rivaroxaban and 565.6 (95% CI 541.8–590.2) for LMWH with adjusted HR 0.48 (95% CI 0.34–0.67). Conclusions Rivaroxaban performed similarly to LMWH for patients with CAT for rVTE and major bleeding. An all-cause mortality benefit was observed for rivaroxaban which potentially may be attributed to residual confounding. | es |
| dc.description.fil | Fil: Linder, Marie. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia | |
| dc.description.fil | Fil: Ekbom, Anders. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia | |
| dc.description.fil | Fil: Brobert, Gunnar. Consultant for Bayer AG; Alemania | |
| dc.description.fil | Fil: Vogtländer, Kai. Bayer AG; Alemania | |
| dc.description.fil | Fil: Balabanova, Yanina. Bayer AG; Alemania | |
| dc.description.fil | Fil: Becattini, Cecilia. Università di Perugia; Italia | |
| dc.description.fil | Fil: Carrier, Marc. University of Ottawa; Canadá | |
| dc.description.fil | Fil: Cohen, Alexander T.. Kings College London (kcl); | |
| dc.description.fil | Fil: Coleman, Craig I.. University of Connecticut; Estados Unidos | |
| dc.description.fil | Fil: Khorana, Alok A.. Cleveland Clinic and Case Comprehensive Cancer Center; Estados Unidos | |
| dc.description.fil | Fil: Lee, Agnes Y. Y.. BC Cancer; Canadá. University of British Columbia; Canadá | |
| dc.description.fil | Fil: Psaroudakis, George. Bayer AG; Alemania | |
| dc.description.fil | Fil: Abdelgawwad, Khaled. Bayer AG; Alemania | |
| dc.description.fil | Fil: Rivera, Marcela. Consultant for Bayer AG; Alemania | |
| dc.description.fil | Fil: Schaefer, Bernhard. Bayer AG; Alemania | |
| dc.description.fil | Fil: Giunta, Diego Hernan. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Linder, Marie; Ekbom, Anders; Brobert, Gunnar; Vogtländer, Kai; Balabanova, Yanina; et al.; Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: A Swedish national population-based register study; Springer; Journal of Thrombosis and Thrombolysis; 5-2024; 1-11 | es |
| dc.identifier.eissn | 1573-742X | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/240255 | |
| dc.journal.ciudad | Berlín | es |
| dc.journal.pagination | 1-11 | es |
| dc.journal.pais | Alemania | es |
| dc.journal.title | Journal of Thrombosis and Thrombolysis | es |
| dc.language.iso | eng | es |
| dc.publisher | Springer | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/10.1007/s11239-024-02992-1 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1007/s11239-024-02992-1 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by/2.5/ar/ | * |
| dc.subject | Cancer-associated thrombosis | es |
| dc.subject | Rivaroxaban | es |
| dc.subject | Low molecular weight heparin | es |
| dc.subject | Recurrent venous thromboembolism | es |
| dc.subject | Major bleeding | es |
| dc.subject.classification | Hematología | es |
| dc.subject.classification | Medicina Clínica | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: A Swedish national population-based register study | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.48bb93ad-773f-4731-b427-45da7307aad1_B.pdf
- Tamaño:
- 1.27 MB
- Formato:
- Adobe Portable Document Format